Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


British Oxfam Urges Thailand Not To Scrap Compulsory-Licensing Policy

This article was originally published in PharmAsia News

Executive Summary

Oxfam, an England-based non-government organization, called on the new government in Thailand to maintain the compulsory-licensing policy of the previous government as a way to keep the prices of life-saving drugs affordable. The group's HIV/AIDS director expressed his concern based on the new government's decision to review the policy. The director said the actions of the previous military-led administration made key AIDS drugs, Bristol-Myers Squibb's Stocrin (efavirenx), sold in the United States as Sustiva, and Abbott Laboratories' version Kaletra (lopinavir, ritonavir), more accessible to more than 120,000 patients. (Click here for more

You may also be interested in...

AbbVie Investors Look For Stabilizing Botox Revenues In Q3 Financials

Reporting its first full quarter of financials since merging with Allergan, AbbVie will be scrutinized for whether its optimistic talk of a quick Botox rebound actually happened.

COVID-19 Could Drive UK OTC Rises

Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.

Sandoz Keeps Tabs On Teva Skinny Label Ruling

As one of the leading players in the US, albeit with a declining core business, Sandoz is naturally watching developments from the Federal Circuit’s precedential ruling on induced infringement for carved out indications. Management discussed the topic as Sandoz reported third-quarter financials.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts